Mediclinic International plc (LON: MDC), a diversified private healthcare services group, today announced that its Mediclinic Southern Africa division has received approval for its proposed acquisition of a controlling share in Matlosana Medical Health Services Proprietary Limited, based in Klerksdorp in the North-West Province of South Africa. The acquisition includes two multi-disciplinary hospitals namely the 185-bed Wilmed Park Hospital and the 62-bed Sunningdale Hospital. In addition, the acquisition includes a 51% share in the 50-bed Parkmed Neuro Clinic psychiatric hospital.
Mediclinic Southern Africa initiated the acquisition process in 2015. Following various approval processes, the matter was referred to the Competition Appeal Court which has now ruled in favour of the acquisition, with an expected effective date around the middle of 2020.
Koert Pretorius, Chief Executive Officer of Mediclinic Southern Africa, said:
“We are delighted to expand our current care offering within the North West Province of South Africa. Mediclinic remains focused on delivering high-quality healthcare services across the continuum of care and an excellent client experience. The Wilmed Park Hospital has consistently been recognised as one of the best hospitals within the North West Province and we are excited to work with the many doctors, nurses and staff at Matlosana to build on that reputation.
“The existing management team at the hospital will remain in place to ensure that the business continues to deliver the same high levels of care under the Mediclinic brand, as we expand our focus on delivering accessible, quality care at the best possible value for our patients.”
Marius van Tonder, CEO of Matlosana Health Services Proprietary Limited, said:
“We look forward to a new era alongside Mediclinic where we have the opportunity to integrate the strengths of our two organisations towards providing expanded access to expertise for our patients.”
About Mediclinic International
Mediclinic is an international private healthcare services group, established in South Africa in 1983, with divisions in Switzerland, Southern Africa (South Africa and Namibia) and the United Arab Emirates.
The Group’s core purpose is to enhance the quality of life.
Its vision is to be the partner of choice that people trust for all their healthcare needs.
Mediclinic is focused on providing specialist-orientated, multi-disciplinary services across the continuum of care in such a way that the Group will be regarded as the most respected and trusted provider of healthcare services by patients, medical practitioners, funders and regulators of healthcare in each of its markets.
As at 1 February, Mediclinic comprised 77 hospitals, five sub-acute hospitals, 14 day case clinics and 22 outpatient clinics. Hirslanden operated 17 hospitals, two day case clinics and three outpatient clinics in Switzerland with more than 1 900 inpatient beds; Mediclinic Southern Africa operations included 53 hospitals (three of which in Namibia), five sub-acute hospitals and 10 day case clinics (four of which operated by Intercare) across South Africa, and more than 8 500 inpatient beds; and Mediclinic Middle East operated seven hospitals, two day case clinics and 19 outpatient clinics with more than 900 inpatient beds in the United Arab Emirates.
The Company’s primary listing is on the London Stock Exchange in the United Kingdom, with secondary listings on the JSE Ltd in South Africa and the Namibian Stock Exchange in Namibia.
Mediclinic also holds a 29.9% interest in Spire Healthcare Group plc, a leading private healthcare group based in the United Kingdom and listed on the LSE.
